Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 773-780

  Johnson, C A ^a   Kilpatrick, D ^a   von Roemeling, R ^a   Langer, C ^a   Graham, M A ^a   Greenslade, D ^a   Kennedy, G ^a   Keenan, Eileen ^a   O'Dwyer, P J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; TIRAPAZAMINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL KILLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DNA DAMAGE; FATIGUE; FEMALE; HUMAN; HYPOXIC CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSITIZATION; SOLID TUMOR; VOMITING;

EID: 0031028873     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.773     Document Type: Article

References (40)

1. Vaupel P, Kallinowski F, Okunief F: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 49:6449-6465, 1989
2. Bush RS, Jenkin RDT, Allt WEC, et al.: Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 37:302-306, 1978 (Suppl 3)
3. O'Dwyer PJ, LaCreta FP, Walczak J, et al.: Phase I clinical, pharmacokinetic, and biochemical study of the nitroimidazole sensitizer SR2508 (etanidazole) in combination with cyclophosphamide. Br J Cancer 68:756-766, 1993
4. Coleman CN, Bump EA, Kramer RA: Chemical modifiers of cancer treatment. J Clin Oncol 6:709-733, 1988
5. Hirst DG, Horsman MR, Brown JM, et al.: The effect of timing on chemosensitization by clinical levels of SR2508. Int J Radiat Oncol Biol Phys 10:1641-1645, 1984
6. Zeman EM, Brown JM, Lemmon MJ, et al.: SR4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12:1239-1242, 1986
7. Zeman EM, Baker MA, Lemmon MJ, et al.: Structure-activity relationships for benzotriazine di-N-oxides. Int J Radiat Oncol Biol Phys 16:977-981, 1989
8. Holden SA, Teicher BA, Ara G, et al.: Enhancement of alkylating agent activity by SR4233 in the FSaIIc murine fibrosarcoma. J Natl Cancer Inst 84:187-193, 1992
9. Zeman EM, Brown JM: Pre- and post-irradiation radiosensitization by SR4233. Int J Radiat Oncol Biol Phys 16:967-971, 1989
10. Sun JR, Brown JM: Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR4233 in a murine carcinoma. Cancer Res 49:5664-5670, 1989
11. Herman TS, Teicher BA, Coleman CN: Interaction of SR4233 with hyperthermia and radiation in the FSaIIc murine fibrosarcoma tumor system in vitro and in vivo. Cancer Res 50:7745-7749, 1990
12. Zeman EM, Lemmon MJ, Brown JM: Aerobic radiosensitization by SR4233 in vitro and in vivo. Int J Radiat Oncol Biol Phys 18:125-132, 1990
13. Dorie MJ, Brown JM: Tumor-specific, schedule-dependent interaction between tirapazamine (SR4233) and cisplatin. Cancer Res 53:4633-4636, 1993
14. Investigators' Brochure: Tirapazamine. Sanofi-Sterling-Winthrop, 1995
15. Baker MA, Zeman EM, Hirst VK, et al.: Metabolism of SR4233 by Chinese hamster ovary cells: Basis of selective hypoxic cytotoxicity. Cancer Res 48:5947-5952, 1988
16. Laderoute K, Rauth AM: Identification of two major reduction products of the hypoxic cell toxin 3-amino-1,2,4-benzotriazine-1,4-dioxide. Biochem Pharmacol 35:3417-3420, 1986
17. Laderoute K, Wardman P, Rauth AM: Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR4233). Biochem Pharmacol 37:1487-1495, 1988
18. Walton MI, Workman P: Enzymology of the reductive bioactivation of SR4233. Biochem Pharmacol 39:1735-1742, 1990
19. Miller AB, Hoogstraten B, Staquet M, et al.: Reporting results of cancer treatment. Cancer 47:207-214, 1981
20. Graham MA, Senan S, Robin H Jr, et al.: Dose escalation strategy and phase I pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in patients. Clinical Cancer Res (to be submitted)
21. Rowland M, Tozer TN: in Clinical Pharmacokinetics: Concepts and Applications. Philadelphia, PA, Lea and Febiger, 1989, pp 34-47
22. Calvert H, Judson I, van der Vijgh WJF: Platinum complexes in cancer medicine: Pharmacodynamics in relation to toxicity and therapeutic activity, in Workman P, Graham MA (eds): Cancer Surveys, vol 17. Pharmacokinetics and Cancer Chemotherapy. New York, NY, Cold Spring Harbor Laboratory, 1993, pp 189-217
23. Gandara DR, Crowley T, Livingston RB, et al.: Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group. J Clin Oncol 11:873-878, 1993
24. Senan S, Rampling R, Graham M, et al.: Tirapazamine (SR4233) induced ototoxicity following single agent administration by continuous intravenous infusion. Ann Oncol 5:135, 1994
25. Rodriguez GI, Valdivieso M, Von Hoff DD, et al.: A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 15:1144, 1996 (abstr)
26. Doherty N, Hancock SL, Kaye S, et al.: Muscle cramping in phase I clinical trial of tirapazamine (SR4233) with and without radiation. Int J Radiat Oncol Biol Phys 29:379-382, 1994
27. Ara G, Coleman CN, Teicher BA: SR4233 (tirapazamine) acts as an uncoupler of oxidative phosphorylation in human MCF-7 breast carcinoma cells. Cancer Lett 85:195-203, 1994
28. 2 tension measurements. Cancer Res 51:3312-3322, 1991
29. Halbherr T, Yao K-S, Johnson SW, et al.: Affects of tirapazamine (WIN 59075, SR4233) on the activity and cellular pharmacology of platinum compounds. Proc Am Assoc Cancer Res 37:604, 1996 (abstr)
30. Gatenby RA, Kessler HB, Rosenblum JS, et al.: Oxygen distribution in squamous cell carcinoma metastases and its relationship to the outcome of therapy. Int J Radiat Oncol Biol Phys 14:831-838, 1988
31. Mannan RH, Mercer JR, Weibe LI, et al.: Radioiodinated azomycin pyranoside (IAZP): A novel non-invasive marker for the assessment of tumor hypoxia. J Nucl Biol Med 36:60-67, 1992
32. Kusumoto T, Teicher BA, Holden SA, et al.: Reversal of drug resistance by exposure of MCF-7 or MCF-7/CDDP human breast carcinoma cells to SR4233 or etanidazole under hypoxic conditions. Int J Oncol 3:205-211, 1993
33. Khan S, O'Brien PJ: Molecular mechanisms of tirapazamine (SR4233, WIN 59075)-induced hepatocyte toxicity under low oxygen concentrations. Br J Cancer 71:780-785, 1995
34. Chen S, Knox R, Friedlos F, et al.: Reductive activation of antitumor drugs by NAD(P)H: quinone acceptor oxidoreductase (NQ01). A study involving mouse-rate chimeric enzymes and site-specific mutants. Proc Am Assoc Cancer Res 36:503, 1995 (abstr)
35. Plumb JA, Gerritsen M, Workman P: DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone E09. Br J Cancer 70:1136-1143, 1994
36. Patterson AV, Robertson N, Houlbrook S, et al.: The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR4233). Int J Radiat Oncol Biol Phys 29:369-372, 1994
37. Workman P, Stratford IJ: The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metast Rev 12:73-82, 1993
38. Graham MA, Robin H Jr, Senan S, et al.: A pharmacokinetically guided dose escalation strategy for WIN 59075: Toxicity and pharmacokinetic investigations in Balb/C mice following a single intravenous injection. Sterling Winthrop Pharmaceuticals Research Division, study report no. 1107-92-REC-6735-59075, October 7, 1992
39. Johnson JA: Pharmacokinetics and excretion of 14C WIN 59075 following a single intravenous administration to male Sprague-Dawley rats. Sterling Winthrop Pharmaceuticals Research Division, study report no. 291, August 14, 1991
40. Johnson JA: Further studies on the disposition of 14C WIN 59075 following a single intravenous administration to male Sprague-Dawley rats. Sterling Winthrop Pharmaceuticals Research Division, study report no. 1039, December 13, 1993